Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20365263 | 0.75 | AOC3 (0.38) | CNR2 | |
| SCHEMBL91618 | 0.75 | AOC3 (0.32) | CNR2 | |
| SCHEMBL16232109 | 0.74 | GRM5 (0.37) | — | |
| SCHEMBL2869278 | 0.74 | NOTUM (0.40) | CNR2 | |
| SCHEMBL7279535 | 0.74 | — | — | |
| SCHEMBL478959 | 0.74 | CNR2 (0.33) | CNR2 | |
| SCHEMBL2869276 | 0.74 | AOC3 (0.31) | CNR2 | |
| SCHEMBL10025201 | 0.74 | AOC3 (0.31) | CNR2 | |
| SCHEMBL10058001 | 0.72 | ALDH1A1 (0.42) | CNR2 | |
| SCHEMBL21325031 | 0.71 | CXCR3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0833638-A1 | USE OF IMIDAZO 1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5668282-A | 4,5-cyclicimidazo[1,5-A]quinoxalines | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5574038-A | 5,6-cyclicimidazo [1,5-a] Quinoxalines | THE UPJOHN COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5541324-A | Imidazo[1,5-A]quinoxalines | THE UPJOHN COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1992022552-A1 | IMIDAZO[1,5-a]QUINOXALINES | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |